←Back to Expert Scholars
Translational Medicine / 转化医学Lung Cancer Immunotherapy
Martin Reck
MD, PhD
🏢LungenClinic Grosshansdorf🌐Germany
Head of Department of Thoracic Oncology
95
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Martin Reck led KEYNOTE-024 which established pembrolizumab monotherapy as first-line treatment for PD-L1 high metastatic non-small cell lung cancer. He is one of the most influential thoracic oncology clinical trialists in Europe.
Share:
🧪Research Fields 研究领域
NSCLC immunotherapy
KEYNOTE-024
first-line pembrolizumab
PD-L1 biomarker
lung cancer trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Martin Reck 的研究动态
Follow Martin Reck's research updates
留下邮箱，当我们发布与 Martin Reck（LungenClinic Grosshansdorf）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment